NP / PA
Cedars Tower Medical Group, INC
Cedars Tower Medical Group, INC was paid $157K by Medicaid between Jan 2018 and Oct 2024, across 10 billing codes. Its largest line is 87811, Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) — 60% of everything it billed.
33Billing provider infoCEDARS TOWER MEDICAL GROUP, INC
LOS ANGELES, CA 90048
LOS ANGELES, CA 90048
33aNPI1689939787assigned 07/05/2012
33bProvider typePrimary Care Nurse Practitioner
28Total paid$157K
24GClaims8,737
24DCodes billed10
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Primary Care Nurse Practitioner providers in California
Rank by total paid#7 of 19
Median peer was paid$56K
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 174 | $2K | |
| 2019 | 245 | $4K | |
| 2020 | 420 | $9K | |
| 2021 | 1,079 | $22K | |
| 2022 | 5,183 | $112K | |
| 2023 | 707 | $4K | |
| 2024incomplete | 929 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 60% | 2,722 | 2,089 | $94K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 1,412 | 1,311 | $19K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 2,120 | 1,650 | $18K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 2,066 | 1,753 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.4% | 146 | 131 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 104 | 52 | $866.10 |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 35 | 35 | $655.07 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16 | 16 | $300.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 104 | 52 | $33.08 |
| 36415 | Collection of venous blood by venipuncture | 0% | 12 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIEVSKY, ALINA (VICE-PRESIDENT)